Effects of vitamin E and sesamin on hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats.
The preventive effects of sesamin, a lignan from sesame oil, and vitamin E on hypertension and thrombosis were examined using stroke-prone spontaneously hypertensive rats (SHRSP). At 5 weeks of age the animals were separated into four groups: (i) a control group; (ii) a vitamin E group, which was given a 1,000 mg alpha-tocopherol/kg diet; (iii) a sesamin group, given a 1,000 mg sesamin/kg diet; and (iv) a vitamin E plus sesamin group, given a 1,000 mg alpha-tocopherol plus 1,000 mg sesamin/kg diet for 5 weeks from 5 to 10 weeks of age. Resting blood pressure was measured by the tail-cuff method once weekly. A closed cranial window was created and platelet-rich thrombi were induced in vivo using a helium-neon laser technique. The number of laser pulses required for formation of an occlusive thrombus was used as an index of thrombotic tendency. In control rats, systolic blood pressure and the amount of urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) became significantly elevated with age. However, the elevation in blood pressure and 8-OHdG were significantly suppressed in rats administrated vitamin E, sesamin, or vitamin E plus sesamin. At 10 weeks, the number of laser pulses required to induce an occlusive thrombus in arterioles of the control group was significantly lower than in the other groups (p<0.05). These results indicate that chronic ingestion of vitamin E and sesamin attenuated each of elevation in blood pressure, oxidative stress and thrombotic tendency, suggesting that these treatments might be beneficial in the prevention of hypertension and stroke.
Noguchi
T
T
Graduate School of Human and Environmental Studies, Kyoto University, Japan. noguchi@brain.riken.go.jp
Ikeda
K
K
Sasaki
Y
Y
Yamamoto
J
J
Seki
J
J
Yamagata
K
K
Nara
Y
Y
Hara
H
H
Kakuta
H
H
Yamori
Y
Y
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects; D001835:Body Weight; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000209:etiology*; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine; D004149:Dioxoles / Q000494:pharmacology*; D004198:Disease Susceptibility; D004338:Drug Combinations; D020022:Genetic Predisposition to Disease; D006973:Hypertension / Q000473:pathology / Q000503:physiopathology*; D017705:Lignans / Q000494:pharmacology*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D051381:Rats; D011918:Rats, Inbred SHR / Q000235:genetics; D020521:Stroke / Q000235:genetics; D013927:Thrombosis / Q000209:etiology*; D014666:Vasomotor System / Q000187:drug effects; D014810:Vitamin E / Q000494:pharmacology*
D004149:Dioxoles; D004338:Drug Combinations; D017705:Lignans; D014810:Vitamin E; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine; C054125:sesamin